AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31535922 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 142
Study 31195099 — intervention group
Group type: EXPERIMENTAL
Intervention: Zumba exercise for 60 minutes twice weekly for 8 weeks
Number of subjects: 98
Study 31195099 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 98
Study 27628624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Care Program (OHCP) administered twice a week for six sessions during in-hospital rehabilitation
Number of subjects: 62
Study 27628624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study 26306996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid molecular testing for Staphylococcus aureus
Number of subjects: 252
Study 26306996 — intervention group
Group type: COMPARATOR
Intervention: Standard of care culture-based testing
Number of subjects: 252
Study 25120809 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Number of subjects: 41
Study 21718522 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with sodium stibogluconate (SSG)
Number of subjects: 189
Study 21718522 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with miltefosine
Number of subjects: 189
Study 21718522 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine alone
Number of subjects: 189
Study 21718522 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 189
Study 19237977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-cardiopulmonary bypass systems
Number of subjects: 0
Study 17713342 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 12
Study 17713342 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 12
Study 17713342 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose + 10% fructose (active control)
Number of subjects: 12
Study 15562367 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 41
Study 15562367 — intervention group
Group type: COMPARATOR
Intervention: No alendronate (control)
Number of subjects: 41
Study 11673772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diet (M; 15% protein, 30% fat, 55% carbohydrate)
Number of subjects: 11
Study 11673772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF; 15% protein, 60% fat, 25% carbohydrate)
Number of subjects: 11
Study 11673772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (HC; 15% protein, 15% fat, 70% carbohydrate)
Number of subjects: 11
Study 9728732 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 77
Study 9728732 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 77
Study 7983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty in severely deformed knees (varus or valgus deformity > 20 degrees)
Number of subjects: 51
Study 7983123 — intervention group
Group type: COMPARATOR
Intervention: Control group (alignment within 5 degrees of normal)
Number of subjects: 51
Study 2714570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with instruction to imagine eating delicious meals
Number of subjects: 2
Study 2714570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with instruction for deep relaxation
Number of subjects: 2
Study 2714570 — intervention group
Group type: COMPARATOR
Intervention: No hypnosis
Number of subjects: 2
Study 772478 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone
Number of subjects: 0
Study 772478 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 0
Study 31912791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily for 52 weeks)
Number of subjects: 498
Study 31912791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 31672941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 17
Study 31672941 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study 28013376 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vacuum wound drainage system
Number of subjects: 1424
Study 28013376 — intervention group
Group type: COMPARATOR
Intervention: Open incision and drainage (I&D)
Number of subjects: 1424
Study 25205417 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention to promote appropriate gestational weight gain
Number of subjects: 873
Study 23408069 — intervention group
Group type: EXPERIMENTAL
Intervention: Strata shunt with valve preset at performance level (PL) 2.5, allowed to be lowered until improvement or radiological signs of overdrainage were met.
Number of subjects: 58
Study 23408069 — intervention group
Group type: COMPARATOR
Intervention: Strata shunt with valve preset at performance level (PL) 1.0 (control group).
Number of subjects: 58
Study 22089718 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 30 mg/d
Number of subjects: 398
Study 22089718 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 100 mg/d
Number of subjects: 398
Study 22089718 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy, 500 mg/d
Number of subjects: 398
Study 22089718 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d) with evacetrapib, 100 mg/d
Number of subjects: 398
Study 22089718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 22089718 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 398
Study 19812027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist intervention (n = 44)
Number of subjects: 127
Study 19812027 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurse intervention (n = 42)
Number of subjects: 127
Study 19812027 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 127
Study 19812027 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal types (morning types)
Number of subjects: 127
Study 16381016 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 cycles of tailored and dose-escalated FEC (5-fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 118
Study 16381016 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of standard FEC followed by high-dose chemotherapy
Number of subjects: 118
Study 16381016 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring BM changes at diagnosis and 6 months post-treatment
Number of subjects: 118
Study 16647907 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride, 60 mg once daily
Number of subjects: 43
Study 16647907 — intervention group
Group type: COMPARATOR
Intervention: Alendronate, 10 mg daily
Number of subjects: 43
Study 14659350 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial and hormonal risk factors for breast cancer, including lower body mass index and nulliparity.
Number of subjects: 102
Study 14659350 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 102
Study 14659350 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in breast density as a potential early indicator of efficacy in chemoprevention trials for breast cancer.
Number of subjects: 102
Study 10337502 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 g three times a day orally for 90 days)
Number of subjects: 22
Study 10337502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7478455 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of tranexamic acid gel
Number of subjects: 0
Study 7478455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1937991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 36
Study 1937991 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no hypnosis)
Number of subjects: 36
Study 6957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg b.i.d.
Number of subjects: 11
Study 6957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg b.i.d.
Number of subjects: 11
Study 6957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg t.d.s.
Number of subjects: 11
Study 6957978 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 11
Study 29631106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein supplementation (36% protein in total calorie)
Number of subjects: 15
Study 29631106 — intervention group
Group type: COMPARATOR
Intervention: Low-protein control supplementation (12% protein in total calorie)
Number of subjects: 15
Study 27424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation integrated into the RehaCom program of attention training
Number of subjects: 20
Study 27424464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no attention training)
Number of subjects: 20
Study 27424464 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 20
Study 25690514 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (hemoglobin <11.3 g/dL; 7 mmol/L)
Number of subjects: 284
Study 25690514 — intervention group
Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (hemoglobin <9.7 g/dL; 6 mmol/L)
Number of subjects: 284
Study 22955567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 24
Study 22955567 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24
Study 20668005 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ enriched young TIL and IL-2 after NMA
Number of subjects: 56
Study 20668005 — intervention group
Group type: COMPARATOR
Intervention: CD8+ enriched young TIL and IL-2 after NMA and 6 Gy total body irradiation
Number of subjects: 56
Study 18434566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice a day
Number of subjects: 4
Study 18434566 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg every day
Number of subjects: 4
Study 18434566 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 4
Study 18434566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: NNECVDSG score tertiles
Number of subjects: 241
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: McSPI score tertiles
Number of subjects: 241
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 241
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 241
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracardiac arteriopathy
Number of subjects: 241
Study 17060040 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent/emergency operation
Number of subjects: 241
Study 12612228 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Multimedia Program for Asthma Control and Tracking
Number of subjects: 228
Study 12612228 — intervention group
Group type: COMPARATOR
Intervention: Traditional patient education
Number of subjects: 228
Study 10990051 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid pattern laser photocoagulation plus arterial crimping (group B)
Number of subjects: 72
Study 10990051 — intervention group
Group type: COMPARATOR
Intervention: Grid pattern laser photocoagulation alone (group A)
Number of subjects: 72
Study 9374590 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sharp bend curves
Number of subjects: 0
Study 9374590 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intermediate forms of flow-volume curves
Number of subjects: 0
Study 1283476 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + galanin (500 micrograms in 100 ml saline)
Number of subjects: 14
Study 1283476 — intervention group
Group type: COMPARATOR
Intervention: GHRH + saline (100 ml)
Number of subjects: 14
Study 2413379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (vinblastine 6 mg/m2 i.v., bleomycin 15 mg i.m., methotrexate 40 mg/m2 i.v., cyclophosphamide 400 mg/m2 i.v., 5-fluorouracil 5 mg/kg i.v.)
Number of subjects: 68
Study 2413379 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 68
Study 29884413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 361
Study 29884413 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (IC)
Number of subjects: 361
Study 29884413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361
Study 27611751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-Ceramic Fixed Dental Prosthesis (MC-FDP)
Number of subjects: 34
Study 27611751 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Ceramic Fixed Dental Prosthesis (AC-FDP)
Number of subjects: 34
Study 27611751 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Fully Dentate, n=20)
Number of subjects: 34
Study 27611751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' Satisfaction
Number of subjects: 34
Study 27611751 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionals' Esthetic Evaluation
Number of subjects: 34
Study 24071935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates, McKenzie and Heckscher training (group I)
Number of subjects: 96
Study 24071935 — intervention group
Group type: COMPARATOR
Intervention: Classical kinetic program (group II)
Number of subjects: 96
Study 22262728 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diabetes-specific cognitive behavioral therapy (CBT) for depression, with minimal therapist support, delivered over 8 lessons.
Number of subjects: 255
Study 22262728 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group for 12 weeks.
Number of subjects: 255
Study 20035979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic reduction during pyeloplasty
Number of subjects: 42
Study 20035979 — intervention group
Group type: COMPARATOR
Intervention: Pelvis-sparing pyeloplasty
Number of subjects: 42
Study 17663804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (4.4 ml/d)
Number of subjects: 64
Study 17663804 — intervention group
Group type: EXPERIMENTAL
Intervention: High 18: 2n‐6 intake (R/K group)
Number of subjects: 64
Study 17663804 — intervention group
Group type: COMPARATOR
Intervention: Low 18: 2n‐6 intake (S/B group)
Number of subjects: 64
Study 15641055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone
Number of subjects: 195
Study 15641055 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD with or without prednisolone
Number of subjects: 195
Study 15641055 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR50 response
Number of subjects: 195
Study 15641055 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR20 response
Number of subjects: 195
Study 15641055 — intervention group
Group type: EXPERIMENTAL
Intervention: No ACR20 response
Number of subjects: 195
Study 12932590 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 177
Study 12932590 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing with short AV delay (DDDR-s)
Number of subjects: 177
Study 12932590 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing with long AV delay (DDDR-l)
Number of subjects: 177
Study 12932590 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing (both DDDR-s and DDDR-l)
Number of subjects: 177
Study 10550443 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 331
Study 10550443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (2.5 mg)
Number of subjects: 331
Study 10550443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 331
Study 10550443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 9110066 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal photography
Number of subjects: 0
Study 9110066 — intervention group
Group type: EXPERIMENTAL
Intervention: Funduscopy
Number of subjects: 0
Study 9110066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach (retinal photography and funduscopy)
Number of subjects: 0
Study 1672539 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (ST)
Number of subjects: 44
Study 1672539 — intervention group
Group type: COMPARATOR
Intervention: Balloon Tamponade (BT)
Number of subjects: 44
Study 6749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g administered 30 min prior to a standardized meal
Number of subjects: 0
Study 6749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g administered immediately before a standardized meal
Number of subjects: 0
Study 6749526 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered with a standardized meal
Number of subjects: 0
Study 6749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 g with the meal
Number of subjects: 0
Study 31221158 — intervention group
Group type: EXPERIMENTAL
Intervention: mCNCP
Number of subjects: 101
Study 31221158 — intervention group
Group type: COMPARATOR
Intervention: pCNCP
Number of subjects: 101
Study 29945500 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hydroxamate HDAC6 inhibitors identified through pharmacophore modeling and molecular docking.
Number of subjects: 0
Study 29945500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacophore model (Hypo1) generated from 26 training set compounds.
Number of subjects: 0
Study 26576715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide in addition to furosemide regimen
Number of subjects: 304
Study 26576715 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to furosemide regimen
Number of subjects: 304
Study 25325773 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lever posterior-tilt plank
Number of subjects: 19
Study 25325773 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lever plank
Number of subjects: 19
Study 25325773 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tilt plank
Number of subjects: 19
Study 25325773 — intervention group
Group type: COMPARATOR
Intervention: Traditional prone plank
Number of subjects: 19
Study 22840666 — intervention group
Group type: COMPARATOR
Intervention: Higher placebo adherence (≥75% adherence)
Number of subjects: 1000
Study 22840666 — intervention group
Group type: COMPARATOR
Intervention: Lower placebo adherence (<75% adherence)
Number of subjects: 1000
Study 19800084 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR)
Number of subjects: 0
Study 18058596 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride (Group A; n=17)
Number of subjects: 52
Study 18058596 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride and metformin (Group B; n=18)
Number of subjects: 52
Study 18058596 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin (Group C; n=17)
Number of subjects: 52
Study 18058596 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 52
Study 16173134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaria officinalis 1500 mg daily (fumitory group)
Number of subjects: 106
Study 16173134 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma xanthorriza 60 mg daily (curcuma group)
Number of subjects: 106
Study 16173134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 11868058 — intervention group
Group type: EXPERIMENTAL
Intervention: tranilast (600 mg/day for 3 months)
Number of subjects: 297
Study 11868058 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 297
Study 11868058 — intervention group
Group type: EXPERIMENTAL
Intervention: tranilast (in restenotic lesions)
Number of subjects: 297
Study 10379748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation
Number of subjects: 121
Study 10379748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate resection
Number of subjects: 121
Study 8882259 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 10 mg
Number of subjects: 101
Study 8882259 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 10 mg
Number of subjects: 101
Study 8882259 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 101
Study 1948092 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SSHA (administered daily for 11 days, with 40 mg SC administered three times every 90 min on the first day)
Number of subjects: 12
Study 1948092 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 20, 40, and 70 mg SSHA (dose-dependent effect tested)
Number of subjects: 12
Study 6656240 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 6
Study 6656240 — intervention group
Group type: COMPARATOR
Intervention: HPLC
Number of subjects: 6
Study 6656240 — intervention group
Group type: COMPARATOR
Intervention: THI-fluorometric method
Number of subjects: 6
Study 30861098 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 299
Study 30861098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 28714563 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min)
Number of subjects: 0
Study 28714563 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 27498662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr. Michaels® product family (Soratinex®)
Number of subjects: 30
Study 27498662 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone aceponate (MPA)
Number of subjects: 30
Study 24994842 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and new antiepileptic drugs (monotherapy)
Number of subjects: 0
Study 24994842 — intervention group
Group type: COMPARATOR
Intervention: First treatment failure
Number of subjects: 0
Study 22813445 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg, 3 times daily for 4 weeks)
Number of subjects: 17
Study 22813445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17